Notifying patients and providers about the rosiglitazone cardiovascular safety alert led to sweeping changes in drug therapy that were initiated by both physicians and patients.
Amy Wei, PharmD
Advertisement
Articles by Amy Wei, PharmD
Advertisement
Latest Updated Articles
- Clinical Consequences of Disseminating the Rosiglitazone FDA Safety Warning
Published: May 1st 2010 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Survey Reveals Clinician Confidence Around Using AI in PA Process
3
How Medicaid Reforms Could Deepen State Coverage Gaps
4
Flow Cytometry Tool Could Improve Treatment Monitoring in MS
5
